QHSLab Reports 40% Revenue Growth in Q2 2026 Despite Net Loss

QHSLab, Inc. reported its financial results for the second quarter of 2026, revealing a revenue increase of 40% year-over-year, reaching $847,490 compared to $605,446 in the same period of 2025. For the first half of 2026, total revenues amounted to $1,576,175, up from $1,250,865 in the prior year. The growth was primarily driven by a significant 86.4% increase in revenue from the Integrated Service Program (ISP), which generated $491,399 in the second quarter and $865,900 in the first half of the year. However, the company also experienced a decline in sales of Allergy Diagnostic Kits, which fell to $196,058 for the quarter and $424,828 for the half-year, down from $197,644 and $462,557, respectively.

Despite the revenue growth, QHSLab reported a net loss of $38,030 for the second quarter and a loss of $65,876 for the first half of 2026, compared to a loss of $52,958 for the second quarter of 2025 and $132,567 for the first half of that year. The company’s operating loss increased to $49,135 for the first half of 2026, reflecting ongoing investments in sales and marketing initiatives, as well as operational infrastructure to support future growth. General and administrative expenses rose significantly, totaling $255,416 for the second quarter and $524,222 for the first half, driven by increased payroll and operational costs.

Operationally, QHSLab's total current assets decreased to $682,933 as of June 30, 2026, down from $883,009 at the end of 2025, primarily due to a reduction in cash and cash equivalents, which fell to $317,392. The company’s total liabilities also decreased to $375,822 from $546,078, largely due to the repayment of loans and the conversion of convertible notes into equity. The company’s accumulated deficit stood at $3,969,427, raising concerns about its ability to continue as a going concern without generating positive cash flows or securing additional financing.

Looking ahead, QHSLab aims to expand its physician network and enhance its recurring revenue base through ongoing product development and strategic marketing efforts. The company plans to introduce additional point-of-care diagnostics and treatments, leveraging its proprietary QHSLab platform to provide value-based healthcare solutions. Management remains optimistic about the potential for increased profitability as the company continues to grow its service-based revenue, although it acknowledges the uncertainties surrounding future cash flows and operating results. The company’s ability to sustain its recent return to profitability will depend on the successful execution of its growth strategy and the overall market conditions.